DUBLIN – In what would be the seventh biotech IPO on the Euronext Exchange this year, Abivax SA is seeking about €44 million (US$49 million) to fund clinical development of its pipeline of antiviral vaccines and drugs.
DUBLIN – Newly published efficacy data for TA-8995, Dezima Pharma BV's cholesterol ester transfer protein (CETP) inhibitor, confirmed the company's claim last year that it may have in its hands the most potent molecule in that emerging drug class of cholesterol control agents.
Anokion SA is spinning out a new start-up, Kanyos Bio Inc., to serve as the vehicle for a development alliance in autoimmune disease with Astellas Pharma Inc., which could be worth up to $760 million in R&D funding, option exercise payments and milestones.
DUBLIN – Glactone Pharma AB, an early stage Swedish firm, is lining up with the big guns of the cancer world at the American Society of Clinical Oncology meeting this week with preclinical proof-of-concept data that could pique some partnering interest.
DUBLIN – Argen-x NV and Leo Pharma A/S entered an alliance, potentially worth more than €104.5 million (US$116 million) on the development of antibody drugs for inflammatory skin conditions, in a move that marks Leo's first foray into biologic drug development.
DUBLIN – Boehringer Ingelheim GmbH is bringing another drug mechanism to bear on nonalcoholic steatohepatitis (NASH), by exercising an option to in-license PXS4728A, a dual semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor from Pharmaxis Ltd. for €27.5 million (US$31.4 million) up front with about $570 million more to come in milestones.
DUBLIN – Boehringer Ingelheim GmbH is bringing another drug mechanism to bear on nonalcoholic steatohepatitis (NASH), by exercising an option to in-license PXS4728A, a dual semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor from Pharmaxis Ltd. for €27.5 million (US$31.4 million) up front with about $570 million more to come in milestones.
DUBLIN – Investors piled into Galapagos NV's thrice-upsized Nasdaq IPO, which grossed $210 million, as part of a global offering that yielded $275 million in total. The greenshoe option, if exercised, would add another $41 million to the total.
DUBLIN – Biontech AG has propelled itself to the front rank of immuno-oncology companies by virtue of a T-cell receptor (TCR) discovery deal with Eli Lilly and Co., under which it is getting $30 million up front plus another $30 million equity investment in its subsidiary firm, Biontech Cell & Gene Therapies GmbH, as well as $300 million in per-product milestones attached to whatever therapies may emerge from the alliance.
DUBLIN – Sensorion SAS, the latest addition to France's lengthening list of quoted biotechnology firms, is among a growing clutch of companies developing drugs for disorders of the inner ear.
